The Kallikrein Inhibitor from Bauhinia bauhinioides (BbKI) shows antithrombotic properties in venous and arterial thrombosis models
Nenhuma Miniatura disponível
Data
2014-05-01
Autores
Brito, Marlon V.
Oliveira, Cleide de
Salu, Bruno R.
Andrade, Sonia A.
Malloy, Paula M. D.
Sato, Ana C.
Vicente, Cristina P.
Sampaio, Misako U.
Maffei, Francisco Humberto de Abreu [UNESP]
Oliva, Maria Luiza V.
Título da Revista
ISSN da Revista
Título de Volume
Editor
Elsevier B.V.
Resumo
The Bauhinia bauhinioides Kallikrein Inhibitor (BbKI) is a Kunitz-type serine peptidase inhibitor of plant origin that has been shown to impair the viability of some tumor cells and to feature a potent inhibitory activity against human and rat plasma kallikrein (Kiapp 2.4 nmol/L and 5.2 nmol/L, respectively). This inhibitory activity is possibly responsible for an effect on hemostasis by prolonging activated partial thromboplastin time (aPTT). Because the association between cancer and thrombosis is well established, we evaluated the possible antithrombotic activity of this protein in venous and arterial thrombosis models. Vein thrombosis was studied in the vena cava ligature model in Wistar rats, and arterial thrombosis in the photochemical induced endothelium lesion model in the carotid artery of C57 black 6 mice. BbKI at a concentration of 2.0 mg/kg reduced the venous thrombus weight by 65% in treated rats in comparison to rats in the control group. The inhibitor prolonged the time for total artery occlusion in the carotid artery model mice indicating that this potent plasma kallikrein inhibitor prevented thrombosis. (C) 2014 Elsevier Ltd. All rights reserved.
Descrição
Palavras-chave
Blood coagulation, Kallikrein, Kunitz inhibitor, Thrombosis, Trypsin inhibitor, Tumor cells
Como citar
Thrombosis Research. Oxford: Pergamon-elsevier Science Ltd, v. 133, n. 5, p. 945-951, 2014.